Evolution of Combined Modality Therapy for Stage III Non–Small-Cell Lung Cancer
July 2nd 2000A number of randomized clinical trials and meta-analyses now support the conclusion that combined modality regimens that include cisplatin (Platinol)-based chemotherapy improve survival in stage III non–small-cell lung